SVB Securities Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at SVB Securities. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from SVB Securities' equity research team. MarketBeat is not affiliated with or endorsed by SVB Securities.Updated 8/29/2023 Brokerage RankingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings0 Last 12 MonthsBuy Ratings0 Last 12 MonthsSell Ratings0 Last 12 Months Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Full History Latest Per Company Show All Ratings Strong Buy Buy Hold Sell Rating All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Price Target Change Action Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsCNTACentessa Pharmaceuticals$39.75+0.1%8/15/2023 Boost Price Target$6.00 ➝ $11.00Outperform00.00%View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 8/15/2023CYTKCytokinetics$78.77+3.0%8/15/2023 Initiated Coverage$58.00Outperform00.00%View details for SVB Securities rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023DMRADamora Therapeutics, Inc. Common Stock$24.15+0.5%8/15/2023 DowngradeOutperform ➝ Market Perform00.00%View details for SVB Securities rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 8/15/2023DSGNDesign Therapeutics$11.10+5.8%8/15/2023 Downgrade$6.00Outperform ➝ Market Perform00.00%View details for SVB Securities rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023EXELExelixis$49.90+2.5%8/8/2023 Initiated Coverage$18.00Market Perform00.00%View details for SVB Securities rating of Exelixis (NASDAQ:EXEL) on 8/8/2023IDYAIDEAYA Biosciences$29.65+4.7%8/8/2023 Initiated Coverage$33.00Outperform00.00%View details for SVB Securities rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023NUVLNuvalent$102.32+1.3%8/8/2023 Initiated Coverage$42.00Market Perform00.00%View details for SVB Securities rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023QTRXQuanterix$2.52+0.4%8/8/2023 Upgrade$30.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Quanterix (NASDAQ:QTRX) on 8/8/2023RLAYRelay Therapeutics$13.02+7.9%8/8/2023 Initiated CoverageOutperform00.00%View details for SVB Securities rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023NVCRNovoCure$17.75+4.4%8/4/2023 Initiated Coverage$51.00Outperform00.00%View details for SVB Securities rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. BLTEBelite Bio$143.36+2.6%7/26/2023 Initiated Coverage$25.00Outperform00.00%View details for SVB Securities rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023NBIXNeurocrine Biosciences$154.67+0.2%7/24/2023 Upgrade$115.00 ➝ $125.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023CYRXCryoPort$14.07+8.0%7/13/2023 Downgrade$30.00 ➝ $10.00Outperform ➝ Market Perform00.00%View details for SVB Securities rating of CryoPort (NASDAQ:CYRX) on 7/13/2023BMYBristol Myers Squibb$58.45+0.2%7/10/2023 Initiated Coverage$66.00Market Perform00.00%View details for SVB Securities rating of Bristol Myers Squibb (NYSE:BMY) on 7/10/2023MLTXMoonLake Immunotherapeutics$17.05+4.2%6/26/2023 Boost Price Target$28.00 ➝ $56.0000.00%View details for SVB Securities rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 6/26/2023EHABEnhabit$13.806/20/2023 Initiated Coverage$10.00Underperform00.00%View details for SVB Securities rating of Enhabit (NYSE:EHAB) on 6/20/2023PEPGPepGen$1.44+4.3%6/14/2023 Lower Price Target$33.00 ➝ $28.0000.00%View details for SVB Securities rating of PepGen (NASDAQ:PEPG) on 6/14/2023UNHUnitedHealth Group$383.30-1.5%6/14/2023 Lower Price Target$625.00 ➝ $560.0000.00%View details for SVB Securities rating of UnitedHealth Group (NYSE:UNH) on 6/14/2023OCSOculis$27.91-0.2%6/12/2023 Initiated CoverageOutperform00.00%View details for SVB Securities rating of Oculis (NASDAQ:OCS) on 6/12/2023CVACCureVac$4.666/8/2023 Initiated Coverage$13.00Outperform00.00%View details for SVB Securities rating of CureVac (NASDAQ:CVAC) on 6/8/2023CSTLCastle Biosciences$20.03+4.3%6/5/2023 Lower Price Target$50.00 ➝ $35.0000.00%View details for SVB Securities rating of Castle Biosciences (NASDAQ:CSTL) on 6/5/2023UHSUniversal Health Services$164.40-1.2%5/26/2023 Upgrade$147.00 ➝ $170.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Universal Health Services (NYSE:UHS) on 5/26/2023AAgilent Technologies$113.64+2.8%5/24/2023 Lower Price Target$170.00 ➝ $145.00Outperform00.00%View details for SVB Securities rating of Agilent Technologies (NYSE:A) on 5/24/2023ARWRArrowhead Pharmaceuticals$77.14+5.4%5/12/2023 Downgrade$40.00Outperform ➝ Market Perform00.00%View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023ABCLAbCellera Biologics$4.57+12.8%5/5/2023 Lower Price Target$16.00 ➝ $15.0000.00%View details for SVB Securities rating of AbCellera Biologics (NASDAQ:ABCL) on 5/5/2023AGIOAgios Pharmaceuticals$28.50+2.8%5/5/2023 Lower Price Target$37.00 ➝ $34.0000.00%View details for SVB Securities rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 5/5/2023ALHCAlignment Healthcare$16.66+1.8%5/5/2023 Lower Price Target$24.00 ➝ $12.0000.00%View details for SVB Securities rating of Alignment Healthcare (NASDAQ:ALHC) on 5/5/2023LNTHLantheus$96.09+3.4%5/5/2023 Boost Price Target$120.00 ➝ $127.0000.00%View details for SVB Securities rating of Lantheus (NASDAQ:LNTH) on 5/5/2023PRVAPrivia Health Group$23.18-0.5%5/5/2023 Boost Price Target$39.00 ➝ $40.0000.00%View details for SVB Securities rating of Privia Health Group (NASDAQ:PRVA) on 5/5/2023REGNRegeneron Pharmaceuticals$649.76+3.1%5/5/2023 Lower Price Target$976.00 ➝ $895.0000.00%View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/5/2023VIRVir Biotechnology$8.88+4.1%5/5/2023 Lower Price Target$43.00 ➝ $42.0000.00%View details for SVB Securities rating of Vir Biotechnology (NASDAQ:VIR) on 5/5/2023DHRDanaher$171.19+2.5%5/1/2023 Initiated Coverage$300.00Outperform00.00%View details for SVB Securities rating of Danaher (NYSE:DHR) on 5/1/2023LLYEli Lilly and Company$1,016.05-0.5%5/1/2023 Boost Price Target$410.00 ➝ $458.0000.00%View details for SVB Securities rating of Eli Lilly and Company (NYSE:LLY) on 5/1/2023HUMHumana$304.64-1.9%4/27/2023 Lower Price Target$640.00 ➝ $600.0000.00%View details for SVB Securities rating of Humana (NYSE:HUM) on 4/27/2023ALVRAlloVir$4.70-0.8%4/26/2023 Boost Price Target$368.00 ➝ $437.0000.00%View details for SVB Securities rating of AlloVir (NASDAQ:ALVR) on 4/26/2023PRTAProthena$9.35+3.1%4/24/2023 Initiated Coverage$80.00Outperform00.00%View details for SVB Securities rating of Prothena (NASDAQ:PRTA) on 4/24/2023BBIOBridgeBio Pharma$68.22+3.4%4/13/2023 Boost Price Target$25.00 ➝ $27.00Outperform00.00%View details for SVB Securities rating of BridgeBio Pharma (NASDAQ:BBIO) on 4/13/2023FDMT4D Molecular Therapeutics$8.47+0.8%4/13/2023 Lower Price Target$14.00 ➝ $13.00Market Perform00.00%View details for SVB Securities rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 4/13/2023ARWRArrowhead Pharmaceuticals$77.14+5.4%4/12/2023 Upgrade$21.00 ➝ $35.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023CORTCorcept Therapeutics$59.06+1.4%4/11/2023 Initiated Coverage$25.00Market Perform00.00%View details for SVB Securities rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023Your book attached (Ad)Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.Download the Safe Trade Options Formula book for free before access closesIPHAInnate Pharma$2.20+8.4%4/10/2023 Boost Price Target$9.00 ➝ $10.0000.00%View details for SVB Securities rating of Innate Pharma (NASDAQ:IPHA) on 4/10/2023REGNRegeneron Pharmaceuticals$649.76+3.1%3/27/2023 Upgrade$834.00 ➝ $976.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023INCYIncyte$97.08+1.5%3/24/2023 Upgrade$61.00Underperform ➝ Market Perform00.00%View details for SVB Securities rating of Incyte (NASDAQ:INCY) on 3/24/2023RAINRain Enhancement Technologies Holdco$2.02+34.7%3/21/2023 Initiated Coverage$11.00Outperform00.00%View details for SVB Securities rating of Rain Enhancement Technologies Holdco (NASDAQ:RAIN) on 3/21/2023CNTACentessa Pharmaceuticals$39.75+0.1%3/17/2023 Initiated Coverage$6.00Outperform00.00%View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023PTCTPTC Therapeutics$71.02+1.0%3/17/2023 Initiated Coverage$48.00Market Perform00.00%View details for SVB Securities rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023HALOHalozyme Therapeutics$68.98+0.4%3/16/2023 Downgrade$42.00Outperform ➝ Market Perform00.00%View details for SVB Securities rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023FULCFulcrum Therapeutics$6.35+7.4%3/10/2023 Lower Price Target$18.00 ➝ $10.0000.00%View details for SVB Securities rating of Fulcrum Therapeutics (NASDAQ:FULC) on 3/10/2023ARGXargenex$804.25+0.8%3/3/2023 Boost Price Target$430.00 ➝ $435.0000.00%View details for SVB Securities rating of argenex (NASDAQ:ARGX) on 3/3/2023AHCOAdaptHealth$10.48+1.3%3/1/2023 Lower Price Target$30.00 ➝ $23.0000.00%View details for SVB Securities rating of AdaptHealth (NASDAQ:AHCO) on 3/1/2023MDRXVeradigm$4.75-5.0%3/1/2023 Lower Price Target$24.00 ➝ $17.0000.00%View details for SVB Securities rating of Veradigm (NASDAQ:MDRX) on 3/1/2023GPCRStructure Therapeutics$36.87+2.8%2/28/2023 Initiated Coverage$33.00Outperform00.00%View details for SVB Securities rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023IRONDisc Medicine$67.03+4.6%2/28/2023 Initiated Coverage$36.00Outperform00.00%View details for SVB Securities rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023MRNAModerna$48.12+5.2%2/24/2023 Downgrade$111.00 ➝ $93.00Market Perform ➝ Underperform00.00%View details for SVB Securities rating of Moderna (NASDAQ:MRNA) on 2/24/2023NKTRNektar Therapeutics$69.49+2.8%2/24/2023 Lower Price Target$75.00 ➝ $45.0000.00%View details for SVB Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023IONSIonis Pharmaceuticals$75.06+1.7%2/23/2023 Lower Price Target$34.00 ➝ $27.0000.00%View details for SVB Securities rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023TDOCTeladoc Health$6.47-2.2%2/23/2023 Upgrade$34.00Market Perform ➝ Outperform00.00%View details for SVB Securities rating of Teladoc Health (NYSE:TDOC) on 2/23/2023ABBVAbbVie$212.51-0.6%2/10/2023 Upgrade$135.00 ➝ $153.00Underperform ➝ Market Perform00.00%View details for SVB Securities rating of AbbVie (NYSE:ABBV) on 2/10/2023CICigna Group$283.36-2.7%2/8/2023 Lower Price Target$335.00 ➝ $309.0000.00%View details for SVB Securities rating of Cigna Group (NYSE:CI) on 2/8/2023VRTXVertex Pharmaceuticals$430.44-0.9%2/8/2023 Lower Price Target$374.00 ➝ $365.0000.00%View details for SVB Securities rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023AMGNAmgen$331.57+0.2%2/2/2023 Lower Price Target$282.00 ➝ $267.0000.00%View details for SVB Securities rating of Amgen (NASDAQ:AMGN) on 2/2/2023METAMeta Platforms$605.06+0.4%2/2/2023 Boost Price Target$220.00 ➝ $255.00Outperform00.00%View details for SVB Securities rating of Meta Platforms (NASDAQ:META) on 2/2/2023DNLIDenali Therapeutics$18.83+4.0%1/30/2023 Initiated Coverage$50.00Outperform00.00%View details for SVB Securities rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023BHVNBiohaven$8.86+5.6%1/24/2023 Initiated Coverage$24.00Outperform00.00%View details for SVB Securities rating of Biohaven (NYSE:BHVN) on 1/24/2023 MarketBeat Community Rating for SVB SecuritiesMarketBeat's community ratings are surveys of what our community members think about SVB Securities and other research firms in the last 90 days. Vote "Outperform" if you believe SVB Securities's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe SVB Securities's recommendations will underperform the broader market over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS2.5out of 5 (last 90 days)2.5 of 5 stars OUTPERFORM VOTES 31 Believe will outperform the market UNDERPERFORM VOTES 31 Believe will underperform the market Best & Worst CallsBest Call0000.0%NASDAQ:IRONInitiated Coverage • Feb 28, 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NASDAQ:VIRXLower Price Target • Aug 15, 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Similarly Rated FirmsTudor PickeringSmall Cap ConsuVentum FinancialCJS SecuritiesWUWunderlichBWS FinancialThinkEquitySummit InsightsFearnley FondsPickering Energy Partners Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
